UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TOSECTION 13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October, 2018
Commission File Number:001-36815
Ascendis Pharma A/S (Exact Name of Registrant as Specified in Its Charter) |
Tuborg Boulevard 5
DK-2900 Hellerup
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.
Form20-F ☒ Form40-F ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
Furnished as Exhibit 99.1 to this Report on Form6-K is the convening notice for the Extraordinary General Meeting of Ascendis Pharma A/S (the “Company”), providing notice to the Company’s shareholders of the Company’s Extraordinary General Meeting to be held on November 2, 2018 at 2:00 pm CET.
Exhibits
Exhibit No. | Description | |
| 99.1 | Convening Notice to Shareholders. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Ascendis Pharma A/S | ||||||||
| Date: October 5, 2018 | By: | /s/ Michael Wolff Jensen | ||||||
| Michael Wolff Jensen | ||||||||
| Chairman and Senior Vice President, General Counsel | ||||||||
